Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. BlossomHill Therapeutics's pretax income for the
six
months ended in Dec. 2025 was $-60.56 Mil.
BlossomHill Therapeutics does not have enough years/quarters to calculate the pretax income for the trailing twelve months (TTM) ended in Dec. 2025.
BlossomHill Therapeutics's pretax margin was %.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics Pre-Tax Income Related Terms
BlossomHill Therapeutics Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics Pre-Tax Income Chart
BlossomHill Therapeutics Annual Data
Trend
Dec24
Dec25
Pre-Tax Income
-30.70
-60.56
BlossomHill Therapeutics Semi-Annual Data
Dec24
Dec25
Pre-Tax Income
-30.70
-60.56
BLSM vs : Pre-Tax Income Comparison
For the Biotechnology subindustry, BlossomHill Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BlossomHill Therapeutics Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where BlossomHill Therapeutics's Pre-Tax Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics (BLSM) has a Pre-Tax Income of $ Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Pre-Tax Income too high?
BlossomHill Therapeutics' current Pre-Tax Income is $ Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Pre-Tax Income compare to ?
BlossomHill Therapeutics' Pre-Tax Income of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Pre-Tax Income is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Pre-Tax Income of $ Mil. The current Pre-Tax Income is $ Mil. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Pre-Tax Income is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score
Get the complete analysis for BLSM
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSM has been successfully added to your 
